Cardiovascular Risk and Events in 17 Low-, Middle-, and High-Income Countries
Salim Yusuf(Population Health Research Institute), Gilles R. Dagenais(Institut universitaire de cardiologie et de pneumologie de Québec), Fernando Laņas(Universidad de La Frontera), Andreas Wielgosz(University of Ottawa), Romaina Iqbal(Aga Khan University), Rafael Díaz(Estudios Clínicos Latinoamérica), Lisheng Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Khalid Yusoff(Universiti Teknologi MARA), Patricio López‐Jaramillo(Universidad De Santander), Martin McKee(London School of Hygiene & Tropical Medicine), Viswanathan Mohan(Madras Diabetes Research Foundation), Sumathi Swaminathan(Hamilton General Hospital), Thandi Puoane(University of the Western Cape), Scott A. Lear(Providence Health Care), Roya Kelishadi(Isfahan University of Medical Sciences), Koon Teo(Population Health Research Institute), Annika Rosengren(Sahlgrenska University Hospital), Sonia S. Anand(Impact), Shofiqul Islam(Population Health Research Institute), Sumathy Rangarajan(McMaster University), Afzalhussein Yusufali(Dubai Health Authority), Omar Rahman(Independent University), Andrzej Szuba(Wroclaw Medical University), Álvaro Avezum(Hospital Alemão Oswaldo Cruz), Jephat Chifamba(University of Zimbabwe), Aytekin Oğuz(Istanbul Medeniyet University), Prem Mony(St.John's Medical College Hospital), Rajesh Kumar(Hamilton General Hospital), Wei Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Jian Bo(Chinese Academy of Medical Sciences & Peking Union Medical College), Rajeev Gupta(Eternal Hospital), Yü Liu(Hamilton General Hospital), Noor Hassim Ismail(Hamilton General Hospital), Annamarie Kruger(North-West University), Fanghong Lu(Hamilton General Hospital), Qinglin Lou(Hamilton General Hospital), Tianlu Liu(Hamilton General Hospital), Matthew McQueen(Population Health Research Institute), Krishnapillai Vijayakumar(Hamilton General Hospital)
Cited by 993
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants
|The Lancet|2016|4.4k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k